MUMBAI, July 19 (Reuters) - Indian drug and medical services startup PharmEasy is in talks with investors to raise $200 million, but at a valuation that could be 15% or even 25% lower than last year's ...
PharmEasy’s revenue from operations fell 14.75% to INR 5,664.2 Cr in FY24 from INR 6,643.9 Cr in FY23 The epharmacy charted somewhat of a turnaround in FY24 as its outgo due to exceptional items ...
PharmEasy managed to cut its net losses by 40% to INR 1,516.8 Cr in FY25 from INR 2,522 Cr in the previous fiscal year The operating revenue for FY25 stood at INR 5,872.1 Cr, up 3.6% from INR 5,664.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback